NTRP tanking. Results were good for those 80 patients who completed the 20 mg dose study, but for those 90 who did not complete the study, there was not statistically significant improvement (as is to be expected if they didn't complete the study). No details about WHY they did not complete. No info on the 40 mg dose results.
So, disaster. Glad I wasn't in very big. Looks like I lose the $300 on my gambling-money call spread that I did, too.
(0)
(0)
Anavex Life Sciences Corp. (AVXL) Stock Research Links